12
Views
3
CrossRef citations to date
0
Altmetric
Articles

Results of Treatment with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) for Non-Hodgkin’s Aggressive Lymphoma Analyzed According to the International Prognostic Index

Pages 446-451 | Published online: 18 Jul 2013

References

  • Shipp MA, Mauch PM, Harris NL. Non-Hodgkin's Lymphomas in: De Vita VT Jr, Hellamn S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 5th edition, Philadelphia: Lippincott, 1997: 2165-2220.
  • Shipp M, Harrington D, Anderson J et al. International Non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994.
  • Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoim-munotherapy. J Clin Oncol 1993; 11: 644–651.
  • Kwak LW, Halper J, Olshen RA et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963–977.
  • Dixon DD, Neilan B, Jones SE et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lym-phoma: the Southwest Oncology Group experience. J Clin Oncol 1986; 4: 295–305.
  • Ciampi A, Bush RS, Gaspodarowicz M. An approach to dassifiying prognostic factors related to survival experience for non-Hodgkin's lymphoma patients: based on a series of 982 patients: 1967-1975. Cancer 1981; 47: 621–627.
  • Hoskins PJ, Ng V, Spinelli JJ, Klimo P, Connors JM. Prognostic variables in patients with diffuse large-cell lym-phoma treated with MACOP-B. J Clin Oncol 1991; 9: 220–226.
  • Stein RS, Greer JP, Flexner JM et al. Large cell lym-phomas: clinical and prognostic features. J Clin Oncol 1990; 8: 1370-1379.
  • Sylmen DJ, Miller TP, Lippman SM et al. Immunobiologic factors predictive of clinical outcome in dif-fuse large-cell lymphoma. J Clin Oncol 1990; 8: 986–993.
  • Grogan TM, Miller TP. Natural history and pretreatment evaluation of non-Hodgkin's lymphomas. In: Cancer Treatment. Haskell CM, ed. Philadelphia: W.B. Saunders Company 1995; 979-1005.
  • Fisher RI, Hubbard SM, De Vita VT, et al. Factors predicting long-term survival in diffuse mixed histocytic or undifferentiated lymphoma. Blood 1981; 58: 45–51.
  • Jagannath S, Velasquez WS, Tucker SL et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4: 859–865.
  • Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991; 9: 211–219.
  • Cowan RA, Harris M, Jones M, Crowther D. DNA content in high and intermediate grade non-Hodgkin's lym-phoma—prognostic significance and clinipathological correla-tions. Br J Cancer 1989; 60: 904–1010.
  • Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has “high risk” disease? Blood 1994; 83: 1165-1173.
  • Fisher RI. Treatment of aggressive non-Hodgkin's lym-phomas: lessons from the past 10 years. Cancer 1994; 74: 2657-2661.
  • Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intesive chemothera-py regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006.
  • Salles G, Shipp MA, Coiffer B. Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin Hematol 1994; 31: 46–69.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.